TVTX - Travere Therapeutics, Inc.

28.63
-0.350   -1.222%

Share volume: 868,325
Last Updated: 03-10-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$28.98
-0.35
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
45%
Profitability 35%
Dept financing 40%
Liquidity 73%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
5.10%
1 Month
-5.26%
3 Months
-18.22%
6 Months
14.52%
1 Year
57.96%
2 Year
258.32%
Key data
Stock price
$28.63
P/E Ratio 
0.00
DAY RANGE
$28.14 - $29.48
EPS 
-$0.29
52 WEEK RANGE
$12.91 - $42.13
52 WEEK CHANGE
$48.57
MARKET CAP 
3.419 B
YIELD 
N/A
SHARES OUTSTANDING 
92.242 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-05-2025
BETA 
1.56
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,436,709
AVERAGE 30 VOLUME 
$1,465,456
Company detail
CEO: Eric M. Dube
Region: US
Website: travere.com
Employees: 460
IPO year: 2008
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Travere Therapeutics, Inc. focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the. treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy.

Recent news